patritumab,sacituzumab govitecan,trastuzumab deruxtecan
daiichi sankyo,gilead sciences,astrazeneca
['patritumab', 'mbc']
her3 expression noted in very similar population, hr+ her2- mbc, by t-dxd and sacituzumab. also we need to remember that patritumab alone did not have any clinical activity, the efficacy of this adc, linker and payload dependent. #asco22 
MD Anderson Cancer Ctr, Breast Med Oncologist, Section Chief of Translational Breast Cancer Research, Executive Director of IBC Program